A critical examination of current HIV therapies

Biotechnology Advances

Volumn 18, Issue 8, 2000, Pages 635-652

  Semple, Jeffrey W ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

DNA; HIV; Therapy; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PREVENTION; VIRUS INFECTION; VIRUS VACCINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034531268     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0734-9750(00)00052-5     Document Type: Article

References (79)

1. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin
2. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses
3. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
4. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
5. What is required of an HIV vaccine?
6. Improving HIV therapy
7. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
8. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
9. Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: Comparative study in cell-free assays and in HIV-infected cells
10. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys
11. A vaccine for HIV type 1: The antibody perspective
12. Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA
13. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
14. A novel vaccine regimen utilizing DNA, vaccinia virus, and protein immunizations for HIV-1 envelope presentation
15. Genetic variation in AIDS viruses
16. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
17. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp 160 protein
18. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
19. DNA-mediated immunization to hepatitis B surface antigen: Longevity of primary response and effect of boost
20. Macromolecular assemblage in the design of a synthetic AIDS vaccine
21. HIV with multiple gene deletions as a live attenuated vaccine for AIDS
22. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine
23. Non-human primate models for AIDS vaccines
24. Strategies used by human immunodeficiency virus that allow persistent viral replication
25. Vaccination with plasmid DNA expressing antigen from genomic or cDNA gene forms induces equivalent humoral immune responses
26. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte response in seronegative adults by a non-replicating host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene
27. The persistence of neutralizing antibodies after revaccination against smallpox
28. HIV-1 DNA vaccines
29. Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes
30. Assembly and morphology of HIV: Potential effect of structure on viral function
31. Gene therapy for infectious diseases: The AIDS model
32. Vaccination of vaccinia-naive adults with HIV-1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial
33. Declining CD4 + T-cell counts in a person infected with nef-deleted HIV-1
34. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
35. From negative factor to a critical role in virus pathogenesis - The changing fortunes of Nef
36. HIV: A new role for Nef in the spread of HIV
37. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
38. RNA virus populations as quasispecies
39. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
40. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression
41. AIDS and HIV vaccines
42. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
43. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
44. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef-and Vpu-inhibitable manner
45. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA
46. Safety and immune responses to a DNA-based human immnunodeficiency virus (HIV) type 1 env/rev vaccine in HIV-infected recipients: Follow-up data
47. Lower in vivo mutation rate of human immnunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
48. HIV vaccines: Combination and prime-boost strategies
49. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
50. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
51. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
52. Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
53. A molecular genetic intervention for AIDS - Effects of a transdominant negative form of Rev.
54. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction
55. In search of AIDS resistant genes
56. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products
57. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
58. In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope
59. Development of HIV vectors for anti-HIV gene therapy
60. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
61. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting
62. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of vaccination
63. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein
64. HIV viral load markers in clinical practice
65. Cloning and functional analysis of multiple spliced mRNAs species of human immunodeficiency virus type 1
66. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs
67. Ups and downs on the road to an HIV vaccine
68. Conference on advances in AIDS vaccine development - 1993. Summary: Correlates of HIV Immunity Working Group
69. Poxvirus-based vectors as vaccine candidates
70. Heterologous protection against influenza by injection of DNA encoding a viral protein
71. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide
72. HIV type 1 variation in World Health Organization sponsored vaccine evaluation sites: Genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains
73. The antigenic structure of the HIV gp120 envelope glycoprotein
74. The HIV-1 envelope glycoproteins: Fusogens, entigens and immunogens
75. AIDS therapies